Received November 12, 2025
Accepted August 24, 2026

Objective: To describe the experience in fertility preservation among oncologic patients managed in a second-level hospital and a private assisted reproduction center, emphasizing clinical characteristics, fertility preservation strategies, and reproductive outcomes. Materials and Methods: A descriptive, retrospective, and observational study was conducted including oncologic patients referred for fertility preservation between January 2020 and December 2024. The final analysis included 54 oncology patients and 54 age-matched controls without cancer undergoing elective oocyte cryopreservation. Descriptive and comparative statistics were performed using SPSS 26.0, with p < 0.05 considered significant. Results: A total of 84 oncologic patients were evaluated. Twenty-seven declined to participate, and three did not meet inclusion criteria; therefore, 54 were included in the final analysis. The most frequent malignancies were breast cancer (44.4%), hematologic malignancies (24%), and gynecologic cancers (16.6%). Oocyte vitrification was performed in 48 patients, while six underwent embryo cryopreservation. The mean number of retrieved oocytes was 12.5 ± 4.8 per cycle, with a mean of 10 mature oocytes vitrified. Ovarian stimulation with letrozole co-administration was used in estrogen-sensitive tumors. No treatment complications or delay in oncologic management were reported. Conclusion: Fertility preservation is a feasible and safe strategy for oncologic patients when coordinated multidisciplinary care is provided. Early referral and individualized protocols, including aromatase inhibitor-based stimulation for hormone-sensitive cancers, optimize reproductive outcomes.